Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Low-molecular-weight heparin is recommended over warfarin for the treatment of acute venous thromboembolism (VTE) in patients with active cancer largely based on results of a single, large trial.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): JAMA

Title: JAMA

ISSN (Electronic): 1538-3598

ISSN (Print): 0098-7484

Publication date (Electronic): Aug 18 2015

Volume: 314

Issue: 7

Affiliations

[1 ] Department of Medicine, University of British Columbia, Vancouver, Canada2British Columbia Cancer Agency, Vancouver, Canada.

[2 ] Department of Vascular Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

[3 ] INSERM U 970, Hôpital Européen Georges-Pompidou, Université Paris Descartes, Paris, France.

[4 ] Department Vascular Medicine, Darmstadt Hospital, Darmstadt, Germany6Center of Thrombosis and Haemostasis, University of Mainz, Mainz, Germany.

[5 ] LEO Pharma, Ballerup, Denmark.

[6 ] Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.

Article

Publisher Item ID: 2428955

DOI: 10.1001/jama.2015.9243

PubMed ID: 26284719

SO-VID: 0f8cda1c-709a-4b90-aed6-600befd9ec2c

History

Data availability:

Comments

Comment on this article

scite_

Cited by 163

See all cited by

- Version 1